BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26657142)

  • 21. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
    Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
    Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancancer analysis identifies prognostic high-APOBEC1 expression level implicated in cancer in-frame insertions and deletions.
    Niavarani A; Shahrabi Farahani A; Sharafkhah M; Rassoulzadegan M
    Carcinogenesis; 2018 Mar; 39(3):327-335. PubMed ID: 29346513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic driver mutations in melanoma.
    Reddy BY; Miller DM; Tsao H
    Cancer; 2017 Jun; 123(S11):2104-2117. PubMed ID: 28543693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.
    Ye Q; Qi F; Bian L; Zhang SH; Wang T; Jiang ZF
    Chin Med J (Engl); 2017 Mar; 130(5):522-529. PubMed ID: 28229982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
    Su D; Zhang D; Chen K; Lu J; Wu J; Cao X; Ying L; Jin Q; Ye Y; Xie Z; Xiong L; Mao W; Li F
    J Exp Clin Cancer Res; 2017 Sep; 36(1):121. PubMed ID: 28882180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SIFT Indel: predictions for the functional effects of amino acid insertions/deletions in proteins.
    Hu J; Ng PC
    PLoS One; 2013; 8(10):e77940. PubMed ID: 24194902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of somatic microsatellite indels identifies driver events in human tumors.
    Maruvka YE; Mouw KW; Karlic R; Parasuraman P; Kamburov A; Polak P; Haradhvala NJ; Hess JM; Rheinbay E; Brody Y; Koren A; Braunstein LZ; D'Andrea A; Lawrence MS; Bass A; Bernards A; Michor F; Getz G
    Nat Biotechnol; 2017 Oct; 35(10):951-959. PubMed ID: 28892075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The challenge of detecting indels in bacterial genomes from short-read sequencing data.
    Steglich M; Nübel U
    J Biotechnol; 2017 May; 250():11-15. PubMed ID: 28267569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
    Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
    Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
    Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Banks KC; Lanman RB; Talasaz A; Parker BA; Kurzrock R
    Oncotarget; 2016 Mar; 7(9):9707-17. PubMed ID: 26848768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterisation of molecular alterations in microdissected archival gliomas.
    Walker C; Joyce KA; Thompson-Hehir J; Davies MP; Gibbs FE; Halliwell N; Lloyd BH; Machell Y; Roebuck MM; Salisbury J; Sibson DR; Du Plessis D; Broome J; Rossi ML
    Acta Neuropathol; 2001 Apr; 101(4):321-33. PubMed ID: 11355303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
    Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
    Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
    Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
    Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic landscapes of cancers: prospects for targeted therapies.
    Bleeker FE; Bardelli A
    Pharmacogenomics; 2007 Dec; 8(12):1629-33. PubMed ID: 18085994
    [No Abstract]   [Full Text] [Related]  

  • 37. [Genetic tests in oncology practice with emphasis on the RET oncogene and VHL tumor suppressor gene].
    Nesković G; Stanojević B; Palmar I; Dimitrijević B
    Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():52-7. PubMed ID: 12584999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
    Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimized detection of insertions/deletions (INDELs) in whole-exome sequencing data.
    Kim BY; Park JH; Jo HY; Koo SK; Park MH
    PLoS One; 2017; 12(8):e0182272. PubMed ID: 28792971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
    Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
    Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.